Biologic and Biosimilar Medications for IBD

Watch the video to learn from expert gastroenterologists about biologic and biosimilar medications that have revolutionized the treatment of IBD. Experts provide an overview of the following:
  • How biologic and biosimilar medications are developed or manufactured;
  • Goals of treatment for people with Crohn's or colitis;
  • How biologic medications are administered;
  • Benefits, risks, and potential side effects of using biologic medications;
  • Different types of biologic and biosimilar therapies approved in Canada including: Adalimumab (Humira®), Infliximab (Remicade® , Inflectra​®, Renflexis​®), Golimumab (Simponi®),  Vedolizumab (Entyvio​®), Ustekinumab (Stelara®);
  • Biotherapies in the pipeline currently in development, undergoing clinical trials, or under review by the FDA and Health Canada;
  • How biologic and biosimilar medications are the same or different; and
  • Safety considerations and potential risks of switching from an originator biologic to a biomilar medication.


Dr. Remo Panaccione (MD, FRCPC) is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary. He is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and has been recently recognized as a 2020 Clarivate Research Scholar for being cited in the top 1% of researchers cited in the world. He is the author of over 300 peer-reviewed articles including publications in journals such as the New England Journal of Medicine, Lancet, JAMA, Nature, and Annals of Internal Medicine. 

His special interest include advanced therapies, biological therapy, and delivery of care. He is a recognized authority on IBD therapeutics and has co-authored numerous guidelines for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn's disease and ulcerative colitis.

Dr. Paul Moayyedi (MD, PhD, MPH, FRCPC) is a Professor of Medicine and Past Director of the Division of Gastroenterology at McMaster University. He holds the Audrey Campbell Chair of Ulcerative Colitis Research and is currently the Assistant Dean of Research at McMaster University. He has published over 425 peer-reviewed articles that have been cited over 56,000 times. He was Co-Editor in Chief of the American Journal of Gastroenterology 2010-2015. 

He is currently the joint Coordinating Editor of the Gut Cochrane Review Group and was co-author of the joint Canadian Association of Gastroenterology and Crohn's Colitis Canada position statement on biosimilars. He is a Principal Investigator of the IMAGINE Network Studies supported by Crohn's and Colitis Canada. 

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest